April 29, 2026

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

Conexiant

April 23, 2026

Does Lithium Improve Agitation After Valproate in Schizophrenia?

Case report suggests benefit in behavioral symptoms with lithium augmentation following adverse events with adjunctive therapy.

Conexiant

April 22, 2026

Serial Bias Differs in Schizophrenia vs Bipolar Disorder

Findings suggest a schizophrenia-like subgroup within bipolar disorder, with implications for targeted treatment approaches

Conexiant

April 17, 2026

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Conexiant

April 16, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 01, 2026

Bipolar Psychosis: Examining Diagnostic Boundaries

Investigators synthesize schizophrenia comorbidity and psychotic symptom profiles across bipolar populations.

Conexiant

May 09, 2024

Time of Day May Impact Aging Predictions

New study reveals that epigenetic age predictions fluctuate significantly throughout the day, emphasizing the need to consider timing in aging assessments.

Conexiant

February 06, 2025

Meds that May Increase Dementia Risk

Antimicrobials, anti-inflammatories, and vaccines were associated with reduced dementia risk, while antipsychotics, antidepressants, and diabetes medications were frequently associated with increased dementia risk.

Conexiant

April 28, 2025

One Third Report HPPD After Psychedelics

Delusional ideation was found to be reduced one month after psychedelic use, researchers reported in a prospective cohort of 654 participants.

Conexiant